trichostatin-a has been researched along with cytidylyl-3--5--guanosine* in 3 studies
3 other study(ies) available for trichostatin-a and cytidylyl-3--5--guanosine
Article | Year |
---|---|
Biochemical analysis of histone deacetylase-independent transcriptional repression by MeCP2.
MeCP2 is an abundant methyl-cytosine-guanine (CG)-binding protein and transcriptional repressor. We developed a biochemical system that exhibits CG methylation-specific transcriptional repression by purified human MeCP2. MeCP2 represses transcription by histone deacetylase (HDAC)-dependent and HDAC-independent mechanisms. Our system appears to recreate the HDAC-independent component of MeCP2-mediated repression and occurs via inhibition of the assembly of transcription preinitiation complexes. At a ratio of approximately one molecule of MeCP2 per two methyl-CG dinucleotides, as found in mammalian neurons, the magnitude of methylation-specific repression was greater than 10-fold. Notably, the HDAC inhibitor trichostatin A had no effect on MeCP2-mediated repression with either naked DNA or chromatin templates. We designed a CG-deficient core promoter that is resistant to MeCP2-mediated repression when placed in a plasmid lacking CG dinucleotides. By using this CG-deficient reporter as a reference, we found that eight CG dinucleotides in the core promoter region are sufficient for strong methylation-specific repression by MeCP2. In contrast, MeCP2 does not repress a construct with 13 CG dinucleotides located ∼1.7 kbp upstream of the promoter. Furthermore, by analysis of C-terminally truncated MeCP2 proteins, we found that binding of MeCP2 to methyl-CG dinucleotides is not sufficient for transcriptional repression. Hence, MeCP2-mediated repression is not due to the simple steric blockage of the transcriptional machinery. These experiments suggest that MeCP2 can function as a global methyl-CG-specific, HDAC-independent repressor. This HDAC-independent mechanism of MeCP2-mediated repression may be important in cells, such as mammalian neurons, that have high levels of CG methylation and MeCP2. Topics: Chromatin; Dinucleoside Phosphates; DNA; DNA Methylation; Electrophoretic Mobility Shift Assay; Gene Expression Regulation; HeLa Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Methyl-CpG-Binding Protein 2; Mutation; Promoter Regions, Genetic; Protein Binding; Transcription Initiation, Genetic; Transcription, Genetic | 2013 |
Epigenetic regulation of androgen receptor gene expression in human prostate cancers.
Epigenetic mechanisms including DNA methylation and histone deacetylation are thought to play important roles in gene transcriptional inactivation. Heterogenous expression of androgen receptor (AR), which appears to be related to variable responses to endocrine therapy in prostate cancer (PCa) may also be due to epigenetic factors. The methylation status of the 5' CpG island of the AR in 3 prostate cancer cell lines and 10 primary and 14 hormone-refractory PCa samples was determined using the bisulfite PCR methods. In DU145, CpG-rich regions of the AR were hypermethylated. By an immunohistochemical analysis, only one PCa sample had no AR expression, the others being heterogenous. Bisulfite sequencing and methylation-specific PCR analysis showed aberrant methylation of AR 5'-regulatory region in 20% of 10 primary and 28% of 14 hormone-refractory PCa samples. To clarify the effect of epigenetic regulation on AR expression, we treated three prostate cancer cell lines with a demethylating agent, 5-aza-2'-deoxycytidine (azaC), and a histone deacetylase inhibitor, Trichostatin A (TSA). In DU145, re-expression of AR mRNA was detected after treatment with azaC and/or TSA. Our results suggest that epigenetic regulations including CpG methylation and histone acetylation may play important roles in the regulation of the AR. Topics: Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Binding Sites; Cyclic AMP Response Element-Binding Protein; Decitabine; Dinucleoside Phosphates; DNA Methylation; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Polymerase Chain Reaction; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; Tumor Cells, Cultured | 2000 |
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.
Cytosine residues in the sequence 5'CpG (cytosine-guanine) are often postsynthetically methylated in animal genomes. CpG methylation is involved in long-term silencing of certain genes during mammalian development and in repression of viral genomes. The methyl-CpG-binding proteins MeCP1 and MeCP2 interact specifically with methylated DNA and mediate transcriptional repression. Here we study the mechanism of repression by MeCP2, an abundant nuclear protein that is essential for mouse embryogenesis. MeCP2 binds tightly to chromosomes in a methylation-dependent manner. It contains a transcriptional-repression domain (TRD) that can function at a distance in vitro and in vivo. We show that a region of MeCP2 that localizes with the TRD associates with a corepressor complex containing the transcriptional repressor mSin3A and histone deacetylases. Transcriptional repression in vivo is relieved by the deacetylase inhibitor trichostatin A, indicating that deacetylation of histones (and/or of other proteins) is an essential component of this repression mechanism. The data suggest that two global mechanisms of gene regulation, DNA methylation and histone deacetylation, can be linked by MeCP2. Topics: Acetylation; Amino Acid Sequence; Animals; Chromosomal Proteins, Non-Histone; Dinucleoside Phosphates; DNA Methylation; DNA-Binding Proteins; Enzyme Inhibitors; Gene Expression Regulation; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Hydroxamic Acids; L Cells; Methyl-CpG-Binding Protein 2; Mice; Molecular Sequence Data; Protein Binding; Recombinant Fusion Proteins; Repressor Proteins; Sin3 Histone Deacetylase and Corepressor Complex; Transcription, Genetic; Transfection | 1998 |